On track for first autoimmune drug approval, Bing Yao steers AstraZeneca spinoff to $150M IPO

Amber Tong

Just days after Viela Bio secured its first PDUFA date for its lead autoimmune drug, the AstraZeneca spinoff is confidently gunning for a $150 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

On track for first autoimmune drug approval, Bing Yao steers AstraZeneca spinoff to $150M IPO

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

On track for first au­toim­mune drug ap­proval, Bing Yao steers As­traZeneca spin­off to $150M IPO

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

On track for first autoimmune drug approval, Bing Yao steers AstraZeneca spinoff to $150M IPO